DSGN · Design Therapeutics, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | — | — | — | $226K | |
| $58.78M | $59.13M | $44.35M | $57.06M | $48.61M | $24.78M | $6.06M | |
| $20.58M | $20.34M | $18.03M | $21.13M | $18.98M | $11.05M | $2.5M | |
| $79.36M | $79.47M | $62.38M | $78.19M | $67.59M | $35.83M | $8.56M | |
| -$79.36M | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M | -$8.33M | |
| — | — | — | — | — | — | -3685.84% | |
| $8.57M | $9.68M | $12.8M | $11.33M | — | — | — | |
| $13.03M | — | — | $11.33M | $4.29M | $298K | $50K | |
| — | $0 | $0 | — | — | — | — | |
| -$70.8M | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M | -$8.28M | |
| — | — | — | — | — | — | -3663.72% | |
| -$71.87M | -$69.86M | -$49.18M | -$63.44M | -$66.42M | -$35.93M | -$8.12M | |
| USD/shares | -$1.18 | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | — |
| USD/shares | -$1.18 | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | — |
| shares | — | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 15.8M |
| shares | — | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 15.8M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 293 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2020 |
|---|---|
| Grant | $200,000 |